The efficacy of parabulbar administration of the Retinalamin peptide bioregulator in the patients with age-related macular degeneration

Abstract

Background: One of the basic problems of contemporary medicine in the diagnosis and treatment remains the age-related macular degeneration (AMD). This is a pathology that affects the macular area of the retina, progresses and manifests itself by chronic degenerative processes of the retina. AMD is the leading cause of central vision loss linked to a sighth less than 0.05 – to the population over 65. Material and methods: The study includes 68 patients (136 eyes) with AMD in the period 2010-2013. The patients were devided into two lots: the basic group (38 patients, 76 eyes) that received parabulbar treatment with peptidic bioreglator Retinalamin and the control group (30 patients, 60 eyes) that followed traditional treatment with angioprotector preparations. Patients were subjected to AV, CVC and TCO examination before and after the treatment. Results: the visual functions improved to the basic group of patients beginning with the fifth day of treatment and continued to grow until the tenth day, maintaining constant for a month from the treatment too. Visual acuity increased in 97.22% cases and scotoma surface decreased by 50,9% in comparison with the control group. Conclusions: Retinalamin facilitates the restoration of retinal photosensitivity for the patients with AMD subjected to the treatment, exerting a specific stimulatory action on retinal photoreceptors, improves functional interactions between pigment epithelium and external segments of photoreceptors that leads to the increase in visual acuity and central scotoma decrease.